Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management

Abstract

Objective

To date, there are no reliable data regarding the actual treatment received by women with refractory obstetric antiphospholipid syndrome (OAPS). The aim of this study was to assess current clinical evidence and new trends in the treatment of refractory OAPS.

Methods

A non-systematic but comprehensive literature search using relevant keywords was made to identify relevant articles published in English from different computerized databases: PubMed (Medline), Google Scholar electronic database search and The Cochrane Library, from January 2000 to March 2012. Studies on the treatment of poor obstetric outcomes in women with OAPS were included. Prospective randomized clinical trials, cohort studies, reviews, systematic reviews and meta-analysis were retrieved.

Results

A total of 130 articles were finally selected for this review, including 17 randomized clinical trials and four meta-analyses. The majority of articles were non-randomized original papers and basic and clinical reviews.

Conclusion

Up to 20% of women with OAPS do not receive the currently recommended therapeutic regimen. Unfortunately, well-designed studies regarding the usefulness of new drugs in refractory OAPS are scarce. Hydroxychloroquine and low-dose prednisolone appear to be useful when added to standard therapy. Current data do not support the use of intravenous immunoglobulins in this field. The role played by double anti-aggregant therapy, fondaparinux, vitamin D, pentoxifylline and TNF-targeted therapies should be tested in well-designed studies.

Keywords

Antiphospholipid antibody complement activation obstetric antiphospholipid syndrome obstetric morbidity refractory treatment

Get full access to this article

View all access options for this article.

References

Yamaguchi

Noriyuki

Kaburaki

. Excessive exposure to anionic surfaces maintains autoantibody response to B2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007; 110: 4312–4318.

Miyakis

Lockshin

Atsumi

. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295–306.

Alijotas-Reig

. Towards the comprehension of the heterogeneity of clinical manifestations related with antiphospholipid antibodies. Med Clin [Barc] 2005; 125: 187–189.

Boffa

M-C

Boinot

de Carolis

. Laboratory criteria of the obstetrical antiphospholipid syndrome [APS]. Data from a multicentre prospective European women cohort. Thromb Haemost 2009; 102: 25–28.

Meroni

Raschi

Grossi

. Obstetric and vascular APS: Same autoantibodies but different diseases? Lupus 2012; 21: 708–710.

Lassere

Empson

. Treatment of antiphospholipid syndrome in pregnancy – a systematic review of randomized therapeutic trials. Thromb Res 2004; 114: 419–426.

Danza

Ruiz-Irastorza

Khamashta

. Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynecol 2012; 26: 65–76.

Scoble

Wijetilleka

Khamashta

. Management of refractory anti-phospholipid syndrome. Autoimmunity Rev 2011; 10: 669–673.

Bates

. Consultative hematology: the pregnant patient pregnancy loss. Haematology Am Soc Hematol Educ Program 2010; 2010: 166–172.

10.

Simchen

Dulitzki

Rofe

. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011; 90: 1428–1433.

11.

Di Prima

FAF

Valenti

Hyseni

. Antiphospholipid syndrome during pregnancy: the state of the art. J Perinatal Med 2011; 5: 41–53.

12.

Alijotas-Reig

Ferrer-Oliveras

. The European Registry on Obstetric Antiphospholipid Syndrome [EUROAPS]: A preliminary first year report. Lupus 2012; 21: 766–768.

13.

de Jesus

dos Santos

Oliveira

. Management of obstetric antiphospholipid syndrome. Curr Rheumatol Rep 2012; 14: 79–86.

14.

Cohen

Berger

Steup-Beekman

. Diagnosis and management of antiphospholipid syndrome. BMJ 2010; 340: 1125–1132.

15.

Ruiz-Irastorza

Egurbide

Ugalde

. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77–78.

16.

Ruiz-Iratorza

Crowther

Branch

Khamashta

. Antiphospholipid syndrome. Lancet 2010; 376: 1498–1509.

17.

Drakeley

Quenby

Farquharson

. Mid-trimester loss – appraisal of a screening protocol. Hum Reprod 1998; 13: 1975–1980.

18.

Galarza-Maldonado

Kourilovitch

Perez-Fernandez

. Obstetric antiphospholipid syndrome. Autoimmun Rev 2012; 11: 288–295.

19.

Cervera

Piette

Font

. Antiphospholipid syndrome: clinical and immunologic manifestations and pattern of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.

20.

Ferrer-Oliveras

Llurba

Cabero-Roura

. Prevalence and clinical usefulness of antiphospholipid and anti-cofactor antibodies in different Spanish preeclampsia subsets. Lupus 2012; 21: 257–263.

21.

Gomez-Puerta

Sanin-Blair

Galarza-Maldonado

. Pregnancy and catastrophic antiphospholipid syndrome. Clin Rev Allergy Immunol 2009; 36: 85–90.

22.

Meroni

. Endothelial cell perturbation by anti-phospholipid antibodies in systemic lupus erythematosus. Lupus 2007; 16(suppl): 17–19.

23.

Koike

. Antiphospholipid antibodies and cell activation. Lupus 2007; 16(suppl): 17–17.

24.

Meroni

Borghi

Raschi

Ventura

. Inflammatory response and the endothelium. Thromb Res 2004; 114: 329–334.

25.

Asherson

Cervera

Wells

. Diffuse alveolar haemorrhage: a non-thrombotic antiphospholipid lung syndrome? Semin Arthritis Rheum 2005; 35: 138–142.

26.

Asherson

Cervera

Shepshelovich

. Non-thrombotic manifestations of the antiphospholipid syndrome: away from thrombosis? J Rheumatol 2006; 33: 1038–1044.

27.

Alijotas-Reig

Vilardell-Tarrés

. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies? Obstet Gynecol Surv 2010; 65: 39–45.

28.

Out

Kooijman

Bruinse

. Histopathological findings in placenta from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynaecol Reprod Biol 1991; 195: 211–220.

29.

Girardi

Redecha

Salmon

. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nature Med 2004; 10: 1222–1226.

30.

Girardi

Berman

Redecha

. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644–1654.

31.

Holers

Girardi

. Complement C3 activation is required for antiphospholipid antibody induced fetal loss. J Exp Med 2002; 195: 211–220.

32.

Meroni

di Simone

Testoni

. Antiphospholipid antibodies as cause of pregnancy loss. Lupus 2004; 13: 649–652.

33.

Magid

Kaplan

Sammaritano

. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 1998; 179: 226–234.

34.

Holmes

Simpson

. Complement and pregnancy: new insights into the immunobiology of the fetal-maternal relationship. Balliere’s Clin Obstet Gynecol 1992; 6: 439–459.

35.

Cunningham

Tichenor

Jr . Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin Immunol Immunopathol 1995; 74: 156–161.

36.

Alijotas-Reig

. The immunological puzzle of recurrent miscarriage. Curr Immunol Rev 2009; 5: 175–186.

37.

Quenby

Bates

Doig

. Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Hum Reprod 1999; 14: 2386–2391.

38.

Tuckerman

Laird

Prakash

. Prognostic value of the measurement of uterine natural killer cells in the endometrium of women with recurrent miscarriage. Hum Reprod 2007; 22: 2208–2213.

39.

Szekeres-Bartho

Faust

Varga

. The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Am J Reprod Immunol 1996; 35: 348–351.

40.

Carp

HJA

Shoenfeld

. Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells - an additional mechanism in a multifactorial process. Rheumatology 2007; 46: 1517–1519.

41.

Levi

Ten Cate

. Disseminated intravascular coagulation. N Engl J Med 1999; 42: 71–75.

42.

Szekeres-Bartho

Kilar

Falkay

. The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: I. Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microbiol 1985; 9: 15–19.

43.

Faust

Laskarin

Rukavina

. Progesterone induced blocking factor inhibits degranulation of NK cells. Am J Reprod Immunol 1999; 42: 71–75.

44.

Carp

HJA

Shoenfeld

. Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells-an additional mechanism in a multifactorial process. Rheumatology 2007; 46: 1517–1519.

45.

Perricone

De Carolis

Giaccomelli

. High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology 2007; 46: 1574–1578.

46.

Berman

Girardi

Salmon

. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 1222–1226.

47.

Meroni

Borghi

Raschi

. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330–339.

48.

Di Simone

Meroni

D’Asta

. Pathogenic role of anti-β2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update 2007; 13: 189–196.

49.

Di Simone

Di Nicuolo

D’Ippolito

. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010; 83: 212–219.

50.

D’Ippolito

Marana

Di Nicuolo

. Effect of low molecular weight heparins on antiphospholipid antibodies-mediated inhibition of endometrial angiogenesis. PLoS ONE 2012; 7: e29660–e29660.

51.

Derksen

de Groot

. Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 2010; 19: 470–474.

52.

Ruiz-Irastorza

Cuadrado

Ruiz-Arruza

. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report to a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 2011; 20: 206–218.

53.

Bates

Greer

Pabinger

. Venous thromboembolism, thrombophilias, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [8th edn]. Chest 2008; 133 (6 Suppl): 844S–886S.

54.

Bates

. Consultative hematology: the pregnant patient pregnancy loss. Haematology Am Soc Hematol Educ Program 2010; 2010: 166–172.

55.

Espinosa

Pierangeli

Gharavi

. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholid antibodies. Thromb Haemost 2002; 87: 518–522.

56.

Edwards

Pierangeli

Liu

. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96: 4380–4384.

57.

Hills

Abrahams

Gonzalez-Timón

. Heparin prevents programmed cell death in human trophosblast. Mol Hum Reprod 2006; 12: 237–243.

58.

Oberkersch

Attoresi

Calabrese

. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res 2010; 125: e240–245.

59.

Lim

. Complement and the antiphospholipid syndrome. Curr Opinion Hematol 2011; 18: 361–365.

60.

Girardi

Redecha

Salmon

. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1226–1226.

61.

Carr

Cho

. Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis. Ann Vasc Surg 2007; 21: 50–55.

62.

Girardi

Redecha

Salmon

. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222–1226.

63.

Samama

Gerotziafas

. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide [fondaparinux]. Thromb Res 2003; 109: 1–11.

64.

Banzato

Frasson

Acqusaliente

. Circulating B2glycoprotein I-IgG anti-B2glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome. Lupus 2012; 21: 784–786.

65.

Amara

Fliert

Rittirsch

. Molecular intercommunications between the complement and coagulation systems. J Immunol 2010; 185: 5268–5236.

66.

Da Pozzo E, Barsoti MC, Benditelli S, et al. Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes. Thromb Res 2012; 130: e113–122.

67.

Ben-Hadj-Khalifa

Hézard

Almawi

. IL-10 modulates fondaparinux inhibition of monocyte-induced thrombin generation. J Throm Thrombolysis 2011; 32: 311–317.

68.

Ruiz-Irastorza

Khamashta

. Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest 2011; 41: 672–678.

69.

Wozniacka

Lesiak

Narbutt

. Chloroquine treatment influences proinflammatory cytokine level in systemic lupus erythematosus patients. Lupus 2006; 15: 268–275.

70.

James DG and Williams WJ. Sarcoidosis and other granulomatous disorders. In: Smith LLH (ed.) Major problems in internal medicine, Philadelphia: W.B. Saunders Co, 1985; 24: 1–254.

71.

Rynes RI. Antimalarial drugs. In: Kelley WN, Harris ED, Ruddyn S and Sledge CB (eds), Textbook of rheumatology, 4th ed. Philadelphia: W.B. Saunders, 1993, pp. 731--742.

72.

Rand

Lapinski

. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104: 2783–2790.

73.

Hunt

de Laat

. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol 2011; 205: 485.e17–23.6.

74.

Rand

Quinn

. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115: 2292–229.

75.

Rand

Quinn As . Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163: 1193–1200.

76.

Rand

Quinn

. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010; 19: 460–469.

77.

ESPRIT Study

Group

Halkes

van Gijn

Kappelle

. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin [ESPRIT]: randomised controlled trial. Lancet 2006; 367: 1665–1673.

78.

Levine

Brey

Joseph

. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke 1992; 23(2 Suppl): 129–132.

79.

George

Cockrell

Adair

. Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic condition in rat placental villous explants. Am J Physiol Regul Integr Comp Physiol 2010; 299: R1629–1633.

80.

Duley

Henderson-Smart

Meher

. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane database Syst Rev 2007; 18: CD004659–CD004659.

81.

Vivaldi

Andreotti

Mazzoni

. A primitive catastrophic antiphospholipid syndrome. Haematologica 1994; 79: 173–176.

82.

Burcoglu-O’Ral

Erkan

Asherson

. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 2002; 29: 2006–2011.

83.

Lubbe

Butler

Palmer

. Fetal survival after prednisone suppression of maternal lupus anticoagulant. Lancet 1983: 1: 1361–1363.

84.

Axelrod L. Glucocortiocoids. In: Kelley NK, Harris ED, Ruddy S, Sledge C (eds) Textbook of rheumatology. 4th ed. Philadelphia, W.B. Saunders Co, 1993, vol 1, pp.779–796.

85.

Sneiderman

Wilson

. Effects of corticosteroids on complement and the neutrophil polymorphonuclear leukocyte. Transplant Proc 1975; 1: 1361–1363.

86.

Quenby

Farquharson

Young

. Successful pregnancy outcome following 19 consecutive miscarriages. Hum Reprod 2003; 18: 2562–2564.

87.

Bramham

Thomas

Nelson-Piercy

. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117: 6948–6951.

88.

Laskin

Bombardieri

Hannah

. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148–153.

89.

Benediktsson

Calder

Edwards

. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol [Oxf] 1997; 46: 161–166.

90.

Akther A, Faridi RM, Das V, et al. In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage. Tissue Antigens 2012; 80: 126–135.

91.

Bayry

Negi

. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011; 7: 349–359.

92.

Porter

LaCoursiere

Scott

. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2006; 2: CD000112–CD000112.

93.

Perricone

De Carolis

Kröegler

. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology 2008; 47: 646–651.

94.

Cervera

. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12: 70–76.

95.

Tuthill

Khamashta

. Management of antiphospholipid syndrome. J Autoimmun 2009; 33: 92–98.

96.

Triolo

Ferrante

Ciccia

. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulins in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48: 728–731.

97.

Branch

Peaceman

Druzin

. A multicenter placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182: 122–127.

98.

Dendrinos

Sakkas

Makrakis

. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 2009; 104: 223–225.

99.

Lopera-Vallejo

Alijotas-Reig

. Antiphospholipid antibodies and recurrent implantation failure in in-vitro fertilization. The debate goes on. Med Clin [Barc] 2011; 137: 697–701.

100.

Szodoray

Bacskó

Lakos

. Combined therapy in pregnancy with primary antiphospholipid syndrome. Orv Hetil 2003; 144: 2411–2413. [Article in Hungarian].

101.

Vaquero

Lazzarin

Valensise

. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisolone plus low-dose aspirin. Am J Reprod Immunol 2001; 45: 174–179.

102.

Carp

HJA

. Intravenous immunoglobulin: effect on infertility and recurrent pregnancy loss. Israel Medical Association Journal (IMAJ) 2007; 9: 877–880.

103.

Moraru M, Carbone J, Alecsandru D, et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish of women with recurrent reproductive failure and expanded CD56[+] cells. Am J Reprod Immunol 2012; 68: 75–84.

104.

Ensom

Stephenson

. A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. Hum Reprod 2011; 26: 2283–228.

105.

Nurmohamed

Dijkmans

. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005; 65: 661–694.

106.

Ramos-Casals

Brito-Zeron

Muñoz

. Autoimmune diseases induced by TNF-targeted therapies. Medicine (Baltimore) 2007; 86: 242–251.

107.

Bongartz

Sutton

Sweeting

. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Journal of American Medical Association (JAMA) 2006; 295: 2275–2285.

108.

Berthelot

De Bandt

Goupille

. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009; 76: 28–34.

109.

Salmon

Alpert

. Are we coming to terms with tumor necrosis factor inhibition in pregnancy? Arthritis Rheum 2006; 54: 2353–235.

110.

Rosner

Haddad

Boulman

. Pregnancy in rheumatology patients exposed to anti-tumor [TNF]-alpha therapy. Rheumatology 2007; 46: 1508–1509.

111.

Bank

LHB

. Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in an infertile patient in response to treatment with anti-tumor necrosis factor monoclonal antibody for Crohn’s disease. Am J Gastroenterol 2002; 97(Abstract): S260–S260.

112.

Ramos-Casals

Roberto-Perez-Alvarez Diaz-Lagares

. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010; 9: 188–193.

113.

Winger

Reed

Ashoush

. Treatment with Adalimumab [Humira^R] and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 2009; 61: 113–120.

114.

Winger

Reed

. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008; 60: 8–16.

115.

Beer

. Th-1/Th-2 natural killer cell activation systemically and locally in the endometrium and therapeutic options. Am J Reprod Immunol 2001; 45: 23–23.

116.

Mangubat

Thaker

Cavalcante

. Etanercept and immune treatment in multiple IVF failures. Am J Reprod Immunol 2001; 45: 24–24.

117.

Chaouat

Assal-Meliani

Martal

. IL-10 prevents naturally occurring fetal loss in the CBAxDBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol 1995; 154: 426–428.

118.

Zhong

Shi

. Effects of Radix scutellariae and Rhizoma atractylodis on LPS-induced abortion and the uterine IL-10 contents in mice. Am J Chin Med 2008; 36: 141–148.

119.

Shaw

Shah

MKH

Williams

. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Cardiol 2009; XX: 113–118.

120.

Song

. Pentoxifylline for endometriosis. Cochrane Database Syst Rev 2012; 1: CD007677–CD007677.

121.

Creus

Fabregues

Carmona

. Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod 2008; 23: 1910–1916.

122.

Bick

. Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost 2001; 7: 241–258.

123.

Letur-Konirsch

Delanian

. Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure who are resistant to hormone replacement therapy. Fertil Steril 2003; 79: 439–441.

124.

Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood 2012; 119: 5859–5870.

125.

Arnson

Amital

Shoenfeld

. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66: 1137–1142.

126.

Agmon-Levin

Blank

Zandman-Goddard

. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011; 70: 145–150.

127.

Hughes

. Hughes syndrome: the antiphospholipid syndrome -a clinical overview. Clin Rev Allergy Immunol 2007; 32: 3–12.

128.

Pierangeli

Vega-Ostertag

Gonzalez

. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med 2007; 9: 1–15.

129.

Raschi

Borghi

Grossi

. Toll-like receptors: another player in the pathogenesis of the antiphospholipid syndrome. Lupus 2008; 87: 214–220.

130.

Sadeghi

Wessner

Laggner

. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006; 36: 361–370.

131.

Broussas

Cornillet- Levefre

Potron

. Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A3 adenosine receptor. Thromb Haemost 2002; 88: 123–130.

132.

Burcuglu-O’Ral

Erkan

Asherson

. Treatment of catastrophic antiphospholipid syndrome with defibrotide: a proposed vascular endothelial cell modulator. J Rheumatol 2002; 29: 2006–2011.

133.

Napoleone

Di Santo

Camera

. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2002; 86: 139–143.

134.

J, Mahmud

Bitterman

. Histone deacetylase inhibitors suppress TF-KappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem 2007; 282: 24 408–24418.

135.

Kinev

Roubey

RAS

. Tissue factor in the antiphospholipid syndrome. Lupus 2008; 17: 952–958.

136.

Raschi

Borghi

Grossi

. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008; 17: 937–942.

137.

Lockhin

Kim

Laskin

. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311–2318.